On Thursday, the Trump Administration announced agreements with pharmaceutical manufacturers Eli Lilly and Novo Nordisk to reduce the prices for GLP-1 drugs.  

When purchased through TrumpRx:

• Ozempic and Wegovy will be $350/month.

• Zepbound and Orforglipron, if approved, will be an average of $346/month.

• If the FDA later approves the Wegovy pill or certain similar “GLP-1” drugs in each company’s pipeline intended to be taken orally rather than as a shot, the initial  dose of those drugs will be $150/month.

For Medicare:

• Ozempic, Wegovy, Mounjaro, and Zepbound will be $245/month (state Medicaid programs will also have access to these prices), with a co-pay of $50/month.

The agreement also provides for reduced costs on other Eli Lilly and Novo Nordisk drugs when purchased through TrumpRx. For example:

• Emgality, a treatment for migraines, will be $299/pen.

• Trulicity, a diabetes medicine will be $389/month per month.

• Certain insulin products, such as NovoLog and Tresiba, will be $35/month.

Eli Lilly and Novo Nordisk will guarantee manufacturer prices on all new drugs that they bring to market, repatriate increased foreign revenue on existing products, and provide every state Medicaid program access to these prices.

Employers and insurers have seen skyrocketing drug spend in their plans/policies due to the increased use of GLP-1 drugs.  Many have added or considered adding plan terms or programs to address this, such as requiring participants get their GLP-1 drug prescribed by a particular provider or participate in a program to learn healthy eating and exercise habits while taking the drugs.  Now, employers and insurers are considering whether to set up an HRA to reimburse the GLP-1 drugs that participants purchase on their own through direct-to-consumer programs.  Note, however, that some of these programs require that the individual not have other coverage for the drug.  It is not clear whether the TrumpRx program will require this or not.

Find the White House Fact Sheet here. 

* * * 

For deep dive coverage, topic-specific analysis, and other Groom benefits, health, and retirement content, visit our website at www.groom.com.